CLINICAL_TRIALS
trial_result
· 2014-06-30
Clinical Trial Update: A Study of Progenta (CDB-4124) in Pre-menopausal Women With Symptomatic Leiomyomata [Phase 1, Phase 2]
Summary
A completed Phase 1/2 study of Progenta (CDB-4124) in pre-menopausal women with symptomatic uterine leiomyomata.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Repros Therapeutics Inc. | Conditions: Uterine Leiomyomata | Phase 1, Phase 2 | Status: COMPLETED